Biosimilar Pricing: Sandoz Vows Not To Make Omnitrope ‘Mistake’ With Filgrastim
Executive Summary
Sandoz, Hospira execs say U.S. payers and consumers will ‘not be disappointed’ in cost savings from products approved under the 351(k) pathway, but warn that price alone may not tell whole story.
You may also be interested in...
Biosimilar Costs Could Exceed Brands In Part D Coverage Gap
Biosimilars are exempt from the 50% discount manufacturers are required to provide on branded drugs for Medicare Part D beneficiaries in the coverage gap, which may result in a higher cost for the biosimilar relative to its reference drug.
Now Comes The Hard Part: Sandoz Must Sell Its Biosimilar
After developing a seemingly ideal application and winning a history-making approval, Sandoz still faces a patent case, and then it would enter territory where it has stumbled before: pricing and marketing a complex product in a crowded market.
Now Comes The Hard Part: Sandoz Must Sell Its Biosimilar
After developing a seemingly ideal application and winning a history-making approval, Sandoz still faces a patent case, and then it would enter territory where it has stumbled before: pricing and marketing a complex product in a crowded market.